Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997784 | 0.81 | CRHR1 (0.62) | CRHR1KDM4EALDH1A1HPGDTP53 | |
| SCHEMBL3146844 | 0.76 | CRHR1 (0.66) | CRHR1KDM4EALDH1A1HPGDCDC7 | |
| SCHEMBL14183025 | 0.70 | KDM4E (0.59) | CRHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL17843992 | 0.69 | CDC7 (0.46) | KDM4EALDH1A1HPGDTP53HSD17B10 | |
| SCHEMBL14183029 | 0.69 | GAA (0.48) | CRHR1KDM4EALDH1A1HPGDPDE4D | |
| SCHEMBL3481769 | 0.68 | HPGD (0.58) | KDM4EALDH1A1HPGDTP53HSD17B10 | |
| SCHEMBL2997417 | 0.67 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL15869833 | 0.66 | FAAH (0.49) | KDM4EALDH1A1HPGDTP53PDE4D | |
| SCHEMBL3481145 | 0.66 | HPGD (0.58) | KDM4EALDH1A1HPGDTP53HSD17B10 | |
| SCHEMBL17844015 | 0.66 | ALDH1A1 (0.59) | KDM4EALDH1A1HPGDTP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184771-A1 | Bicyclic Heterocyclic Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-1961754-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184771-A1 | Bicyclic Heterocyclic Compound | NR3C2, NR3C1, CRHR1 | CRHR1 3/4885KDM4E 3422/4885ALDH1A1 2365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.